Browse Category: Cancer Researcher

Groupon Co-Founder Wants to Create Individualized and Data Driven Treatment with Tempus

In Heidi Harris’ Tech News Spy article “Tempus, Eric Lefkosky, and the Rise of Data Enabled Precision Medicine”, the co-founder of Groupon attempts to change the world of healthcare by providing invaluable data to doctors.

The serial entrepreneur’s latest venture, Tempus, was created to provide modern technology and the benefits to cancer researchers and physicians. The goal is to change the way healthcare is provided to cancer patients by providing individualized treatment plans based on molecular and clinical data.

The company created the “world’s largest library of molecular and clinical data” that is paired with an analytics software to provide the necessary information to doctors. The information pairs genome sequencing data with clinical data to demonstrate which medicines are the most effective for different tumors and different molecular compositions. By doing so, the physicians and researchers will be able to look at the ceaselessly improved information and tailor the treatment to the individual and learn more about Eric.

Though the process of genome sequencing has been around since 2003, it was incredibly expensive. The first genome sequencing was over $100 million. However, with the improvement in technology and science, the cost is around $5,000. Tempus provides access to the information and in doing so allows the specialists to create treatment that is backed by data and more information click here.

Eric Lefkofsky was born on September 2, 1969 to a structural engineer and a school teacher in Michigan. He attended University of Michigan and graduated with honors. He continued his education at the University of Michigan Law School where he received his Juris Doctorate.

Eric Lefkofksy is a dedicated philanthropist. He and his wife began the Lefkofksy Foundation to enhance the quality of human life by reinforcing and supporting scientific, educational, and other charitable causes around the world. He is also on the board of directors at the Children’s Memorial Hospital and for the Art Institute of Chicago.

His entrepreneurial characteristics have driven him to create a variety of other companies along with Tempus. He may be most well known as the co-founder of Groupon, an ecommerce company that provides coupons to local events and activities. He is also the co-founder of InnerWorkings, Echo Global Logistics, Mediaocean, and Lightbank.

The Illustrative Career Of Mikhail Blagosklonny

Mikhail Blagosklonny is an expert in anti-aging medicine and oncology. The scientist has spent his career studying aging and cancer. In addition, he has made exceptional contributions to the fields. Mikhail is an oncology professor at the New York’s Roswell Park Cancer Institute.

Blagosklonny is an alumnus of the First Pavlov State Medical University of St. Petersburg. At the University, he pursued internal medicine for his M.D. After graduating, he enrolled for experimental medicine and cardiology doctorate. His sound educational background saw him earn a position at Ordway Research Institute in Albany, New York. The expert served at the Institute as a senior scientist until 2009 when he moved to the Roswell Park Cancer Institute as the professor of oncology. Since then, he has been at Roswell Park.

Read more:
Hormesis does not make sense except in the light of TOR-driven aging
Live longer!

Throughout his career, Blagosklonny has been interested in cancer and targeted cancer therapies. His research in targeted cancer therapies has focused on how normal cells can be protected from the damages caused by cancer cells. He is also involved in studying the underlying mechanisms of aging and drugs that can be used to slow down aging. This field is called biogerontology.

Mikhail Blagosklonny is known for his hypothesis that claims that TOR signaling plays a critical role in aging and cancer. According to his hypothesis, it is possible to use cancer drugs such as rapamycin to treat aging. Although some scientists are still investigating his claims, Blagosklonny remains optimistic about its success. He has been the most vocal proponent of using rapamycin as an anti-aging drug. Source: https://www.linkedin.com/in/mikhail-blagosklonny-91abb531

Mikhail’s presence at Roswell Park Cancer Institute has served to provide other experts with new outlook at anticancer strategies, cancer therapy, and methods of cancer prevention. These insights will help the institute accelerate and broaden its research. Mikhail Blagosklonny’s research at the firm will also involve looking at the ways in which healthy cells could be protected from radio and chemotherapies. In addition, it will focus on how slowing down organismal aging could prevent cancer, and selective combination of anti-cancer drugs. The scientist will also continue working on his TOR Signaling hypothesis.

Apart from his research on aging and oncology, Blagosklonny is an editor-in-chief of different publications such as Aging, Cell Cycle, and Oncotarget. He is also Cancer Biology & Therapy’s associate editor and editorial board member of Cell Death & Differentiation. The scientist’s editorial roles have seen him edit many publications in the fields of aging and oncology. This opportunity has exposed him to new and radical approaches in the field.

Read more about Mikhail Blagosklonny Research Gate